Enasidenib

How novel agents & individualized treatment approaches are improving outcomes in patients with AML

How genomic testing has influenced treatment approaches and clinical trial design in MPNs

Overall survival by IDH2 mutant allele in late-stage R/R AML patients enrolled in IDHENTIFY

Trends in AML and MDS at ASH 2021

Genomic updates in the field of MPNs

Updates on IDH inhibition in AML

Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246

MDS clinical trials: the European effort

Enasidenib plus azacitidine in newly-diagnosed AML

AML post-transplant maintenance: enasidenib & ivosidenib

AML: new targeted inhibitors as single agents?

Enasidenib for IDH2-mutated MDS

Progress in AML & research at the University of Düsseldorf

Personalized AML therapy with John Byrd: the beat AML trial and more

Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions

Beat AML: promising results with enasidenib for AML in the frontline